Chromatographic medium enables the purification of adenovirus and other viruses in gene therapy and vaccine applications
Amersham Biosciences has made available a chromatographic medium for virus purification.
'Q Sepharose XL virus licensed' enables the purification of adenovirus and other viruses in gene therapy and vaccine applications.
The product enables purification of virus preparations significantly faster than conventional technology with the added benefit of easy scale-up for the production of clinical batches.
Amersham Biosciences has licensed Gencell's patent covering the use of Q Sepharose XL for purification of adenovirus and other viruses.
Customers purchasing the medium from Amersham Biosciences will automatically obtain a license to utilise this scaleable product to purify viruses.
For purification, 'Q Sepharose XL virus licensed' can be used in conjunction with crossflow filtration and chromatography systems such as Akta pilot and bioprocess systems from Amersham Biosciences.
"With viral-based gene therapy and vaccine products now moving into late-stage clinical development, there is a growing need for faster and simpler methods for purifying viral vectors, in particular adenovirus," says Francis Blanche, head of process development at Gencell.
"Q Sepharose XL provides significantly better performance for adenovirus purification than other resins we have tested".
"Chromatographic separation for virus purification offers our customers several advantages over centrifugation techniques," says Guenter Jagschies, vice president marketing, protein separations at Amersham Biosciences.
"Chromatographic purification using Q Sepharose XL requires only a few hours in comparison to as long as 24 hours with centrifugation.
"In addition, the scalability of Q Sepharose XL simplifies the transition to commercial-scale manufacturing of viral-based products."
